Arbutus Biopharma Corporation ABUS Revenue from collaborations and licenses — Revenue

Other product segments

Similar metrics at other companies

AUPHLicense, collaboration and royalty revenue — Revenue

$4.14M+66.1%

VIRLicense and collaboration revenue — Total revenues

-$41K+41.4%

TARSLicense fees and collaboration revenue — Total revenues

$16.67M—

CRNXCollaboration and license revenue — Total Revenue

$428K+18.6%

TVTXLicense and collaboration revenue — Total Revenue

$2.71M-54.1%

NRIXLicense revenue — Revenue

$30M—

Questions, answered.

What is Arbutus Biopharma Corporation's revenue from collaborations and licenses — revenue?

Arbutus Biopharma Corporation (ABUS) reported revenue from collaborations and licenses — revenue of $178.74M in Q1 2026.

How has Arbutus Biopharma Corporation's revenue from collaborations and licenses — revenue changed year-over-year?

Arbutus Biopharma Corporation's revenue from collaborations and licenses — revenue increased by 21912.4% year-over-year, from $812K to $178.74M.

What is the long-term trend for Arbutus Biopharma Corporation's revenue from collaborations and licenses — revenue?

Over 4 years (2021 to 2025), Arbutus Biopharma Corporation's revenue from collaborations and licenses — revenue has grown at a 23.0% compound annual growth rate (CAGR), from $4.68M to $10.71M.

What does revenue from collaborations and licenses — revenue mean?

This metric represents the total revenue generated from strategic partnerships, research collaborations, and the licensing of proprietary intellectual property or technology platforms. It reflects the company's ability to monetize its R&D pipeline and technological assets through external commercial agreements.